StockWatch
·

MARKSANS PHARMA LTD. Q2 FY27 Results

MARKSANSQ2 FY27 Results
Filing
Result:Good· Market: Down#Margin expansion#Broad based

Outlook: Optimistic · Guidance: Maintained

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue940.1711.8%30.5%
Total Income958.3210.6%29.2%
Expenditure764.8215.9%25.7%
PBT193.506.3%45.1%
Net Profit143.5310.0%44.8%
OPM22.79%2.55pp2.73pp
NPM14.98%3.42pp1.62pp
EPS3.1210.1%43.8%
View full financials

Revenue (+30.5% YoY, 6-quarter high) and adjusted PAT (+44.8% YoY) both grew strongly with OPM expanding 20.1%→22.8% YoY, but the sequential cool-off from Q1's record and still-pending gross-margin normalization keep this a strong-but-not-standout quarter for a pharma name judged on revenue growth and margin trend.

MARKSANS · Q2 FY27 · THE VERDICT

Record growth, margin resilience tested

Revenue beat guidance at +30.5% YoY, but profit declined 10% QoQ despite 11.8% revenue growth—₹35 crore in freight, depreciation, and labour headwinds offset gross margin gains. The Q3 profit recovery will define whether this is a temporary cost squeeze or a structural margin problem.

13 Nov 2026 · 6 min read
Q2 Revenue

₹940.2 Cr

+30.5% YoY, +11.8% QoQ

EBITDA Margin

22.8%

+274 bps YoY; H1 24%, tracking 21–22% guidance

PAT

₹143.5 Cr

+44.8% YoY, but -10% QoQ from ₹159 Cr Q1

Gross Margin

58.5%

+135 bps YoY; above 55–56% normalized target

On revenue and margins, Marksans delivered a record quarter. On profit, it stumbled. Quarter-on-quarter, net income fell to ₹143.5 crore from ₹159 crore despite revenue climbing 11.8%—the first sign that cost pressures may be more durable than the call suggests. Understanding where that ₹15.5-crore profit gap came from, and whether it heals in Q3, is the real earnings story.

Where the profit decline came from

The company quantified three Q2 headwinds: freight ₹20 crore (Red Sea disruptions), intangible asset depreciation ₹6–7 crore (QlinIQ and ABCnow acquisitions now amortizing on a finite 10-year schedule), and labour costs ₹8 crore higher year-on-year. That totals ₹34–35 crore in incremental expenses. Yet profit fell only ₹15.5 crore QoQ. The offset came from gross margin expansion—inventory benefits that lifted Q1 wore off, Q2 saw lower sourcing costs, and that gross margin gain (roughly ₹19–20 crore, embedded in the 58.5% print) nearly broke even on the headwinds. The fragility is now apparent: if freight normalizes but labour and depreciation stick, and if gross margin reverts to the 55–56% target as management expects, profit has no cushion for the next stumble.

Freight (Red Sea)

₹20 Cr

Sequential headwind; expected to normalize

Depreciation (QlinIQ, ABCnow)

₹6–7 Cr

New finite-life accounting; recurring for 2+ quarters minimum

Labour inflation

₹8 Cr

YoY headwind; ongoing structural cost

Gross margin offset

~₹20 Cr

Temporary benefit; expected to normalize to 55–56%

Management's claims vs. what holds up

Key on-call claims and their verdict

Record Q2 revenue ₹940 Cr, YoY +30.5%, beating FY27 guidance of 15–20%

Data check

Delivered ₹940.2 Cr, +30.5% YoY. H1 ₹1,781 Cr (+32.9% YoY). Guidance was conservative.

Verdict

Supported

EBITDA margin 22.8%, above 20–21% sustainable target; expect 21–22% by FY27 end

Data check

Q2 22.8%, H1 24%. Running above midpoint; normalization to 21–22% as freight stabilizes and depreciation absorbs.

Verdict

Supported; normalization risk embedded

Europe ₹405 Cr H1 (+65% YoY) now tracking ₹1,000+ Cr 3-year target; $300M U.S. order book in 3 years

Data check

Europe ₹405 Cr confirmed (QlinIQ ₹84 Cr, ABCnow ramping). U.S. price erosion single digits, order book credible. Targets explicit, roadmap clear.

Verdict

Supported; execution risk on M&A synergies

PAT +44.8% YoY shows operational leverage intact

Data check

PAT ₹143.5 Cr YoY +44.8%, but -10% QoQ. YoY leans on weak Q2 FY26 base; QoQ decline flags near-term profit headwind.

Verdict

Overstated (trend deteriorating despite YoY beat)

What changed on this call

  • Europe acceleration formalized: ₹180 Cr FY target exceeded; three M&As (QlinIQ, ABCnow, GmbH) now active

  • U.S. order book target quantified: $225M → $300M over 3 years, with explicit ANDA pipeline

  • Depreciation accounting changed: intangibles to finite 10-year life; ₹6–7 Cr every quarter for 8+ quarters ahead

  • Indian manufacturing acquisition in active dialogue: 12–18 month timeline, 16B units/year target

  • Freight and labour cost headwinds quantified for first time; geopolitical risk explicitly tied to Red Sea

The bull case

Revenue growth is accelerating, not decelerating. At +30.5% YoY, Marksans is far outpacing its prior guidance and building geographic diversification: North America 45%, Europe 43%, each its own market. The European acquisition roadmap (QlinIQ, ABCnow, GmbH) is converting early momentum into structural presence—₹405 Cr H1 on a ₹180 Cr full-year prior target is not a blip. The U.S. order book, now explicitly quantified at $300M in 3 years, is backed by 5–6 pending ANDAs and tangible retailer partnerships. Capex is coming (Indian plant, dosage-form expansion), but balance-sheet strength (₹1,095 Cr net cash) supports both M&A and growth investment without stress. Management's long-term targets (₹5,000–6,000 Cr revenue, Europe ₹1,000+ Cr) are concrete and have operational moats behind them.

The bear case

Profit quality is deteriorating even as revenue accelerates. A ₹15.5-crore QoQ profit decline on 11.8% revenue growth is a profitability miss that no margin-expansion story fully explains. The three cited headwinds (freight ₹20 Cr, depreciation ₹6–7 Cr, labour ₹8 Cr) total ₹34–35 crore and will recur in Q3 unless freight normalizes (geopolitical outcome uncertain) or M&A synergies offset them (execution risk). Depreciation is now ₹6–7 Cr every quarter for at least 8+ quarters—a permanent earnings drag from M&A. Gross margin at 58.5% exceeds the 55–56% normalized target; when it normalizes, that ₹19–20 Cr offset disappears and profit becomes even more vulnerable. The market is pricing in the growth story at ₹322, sitting 31% above the 200-day average and only -10% from all-time high, leaving almost no room for execution stumbles. If Q3 profit doesn't recover alongside seasonal strength, the Hold becomes a Sell.

How the street is positioned

The stock closed at ₹322.15, trading 31% above its 200-day moving average (₹246.02), comfortably above the 50-day (₹318.36) and 20-day (₹305.67). It sits -10.19% from its all-time high of ₹358.7 but +107.84% from its 52-week low of ₹155. The RSI of 56.3 is neutral—neither overbought nor oversold. Volume is normal, not panic or euphoria. FII ownership is steady at 17.47% (up just 0.71 pp QoQ), and DII at 6.19% (down 0.38 pp). No concerning bulk or block deals—only routine Microcurves trading. Institutional positioning is cautiously bullish, not overcommitted. The price action confirms the fundamental story (revenue and geography are strong) but prices in near-term margin challenges (the stock remains -10% from highs despite a beat). A Q3 profit recovery would likely see the stock test the all-time high; a continued decline would trigger a 5–10% retracement. The market is balanced, not fragile.

Risks, ranked by how much they should concern a holder

1. QoQ profit decline recurs in Q3 despite seasonal strength

High

A -10% QoQ PAT decline on +11.8% revenue growth is a profitability miss. If it repeats in Q3 (typically stronger), the margin resilience story breaks, guidance (21–22% EBITDA) will be in doubt, and the stock re-rates lower.

2. Gross margin normalizes from 58.5% to 55–56%

Medium

Gross margin is 135 bps above normalized target. Q1 inventory benefits fading, Q2 sourcing gains temporary. When it normalizes, the ₹19–20 Cr buffer that offset Q2 headwinds disappears.

3. Depreciation ₹6–7 Cr is permanent, not transient

Medium

Changed intangible-asset accounting; QlinIQ and ABCnow now amortize over 10 years. This is baked into earnings for 8+ quarters. Every unplanned rupee of depreciation is a direct PAT miss.

4. Red Sea freight tailwind doesn't materialize; disruptions persist

Medium

₹20 Cr Q2 freight was attributed to geopolitical disruption. If disruptions persist into Q3/Q4, freight stays elevated and the full ₹34–35 Cr headwind waterfall moves against the company.

5. European M&A integration misses synergy targets

Medium

QlinIQ (₹84 Cr revenue H1) and ABCnow (ramping) are moving the dial, but if integration stalls or capex timelines slip, the 3-year ₹1,000+ Cr Europe target is at risk and stock re-rates on execution doubt.

6. U.S. price erosion accelerates beyond single digits

Low

OTC retailer pressure and geopolitical uncertainty are holding price erosion to single digits. If competition intensifies or demand softens, erosion could accelerate and pressure revenue growth.

What to watch next
  • 1 · Q3 PAT recovery

    Seasonally, Q3 is the strongest quarter. If PAT grows alongside revenue, the QoQ decline was a transient cost squeeze. If profit falls again despite seasonal strength, the margin resilience story breaks and Hold becomes Sell.

  • 2 · Freight cost normalization signal

    Management expects ₹20 Cr Q2 freight to normalize. Watch for Q3 colour on Red Sea recovery or continued disruptions. A stuck ₹20 Cr headwind is a permanent earnings drag.

  • 3 · European M&A synergy signals

    QlinIQ contributed ₹84 Cr H1; ABCnow is ramping. Watch for cross-selling signals, Marksans product-introduction timelines into Europe, and German subsidiary path to profitability. This is the long-term growth driver.

Marksans is a geographic diversification story in motion, not a single-region generics player anymore. Revenue growth is genuine, margins are resilient on paper, and the long-term targets (Europe ₹1,000+ Cr, U.S. $300M in 3 years) are credible. But Q2 reveals a company under near-term cost pressure, and profit quality is deteriorating faster than the headline growth suggests.

This is a steady-execution story, not a step-change. The one number to track from here is Q3 profit. Profit growth > 0 (or at minimum profit stability) alongside seasonal strength would justify buying the -10% drawdown from all-time highs. A repeated profit decline would signal execution risk and warrant a reset lower. Until Q3 lands, Hold is the right call.

Informational and educational content only. Not investment advice.